Skip to Main Content

Paper Details

IgM anti-ACE2 autoantibodies in severe COVID-19 activate complement and perturb vascular endothelial function.
JCI Insight
25
2022
ACE2, ACE2-reactive IgM autoantibodies, Anti-ACE2 IgM autoantibodies, Anti-ACE2 IgMs, COVID-, COVID-19, IgG, IgM, SARS, SARS-CoV-2, SARS-CoV-2 receptor, T cell, acute respiratory distress syndrome, angiotensin-converting enzyme 2, anti-ACE2 IgM, anti-ACE2 autoantibodies, endothelial cells, patients, tissue, tissue-engineered, vascular endothelial
Author NameAffiliation
Srinivasan YegnasubramanianJohns Hopkins University School of Medicine
Peter C SearsonJohns Hopkins University School of Medicine
Peter C SearsonInstitute for NanoBioTechnology and.
Peter C SearsonJohns Hopkins University
Lauren M SauerJohns Hopkins Hospital
Lauren M SauerJohns Hopkins Biocontainment Unit, Johns Hopkins University School of Medicine
Lauren M SauerJohns Hopkins Hospital
Lauren M SauerJohns Hopkins Biocontainment Unit, Johns Hopkins University School of Medicine
Oliver Laeyendecker
Oliver LaeyendeckerNational Institute of Allergy and Infectious Diseases
Brian T GaribaldiJohns Hopkins Biocontainment Unit, Johns Hopkins University School of Medicine
Brian T Garibaldi
Richard E RothmanJohns Hopkins Hospital
Andrew Pekosz
Andrew Pekosz
Scott L Zeger
Scott L ZegerBloomberg School of Public Health, Johns Hopkins University
  • 1 - 17

Datasets

Release 1.2